Melanoma-associated antigen peptide-Major Histocompatibility Complex (Melanoma pMHC)

Peptide-Major Histocompatibility Complex (pMHC) molecules on melanoma cells are specialized surface structures that present intracellular protein fragments to the immune system. In the context of melanoma, these complexes consist of HLA class I molecules (frequently HLA-A*02:01) bound to peptides derived from tumor-associated antigens such as gp100, MAGE-A4, NY-ESO-1, or PRAME (Nathan et al., 2021, NEJM; D'Angelo et al., 2024, Lancet). These targets are unique because they allow therapeutic agents to recognize internal oncogenic or lineage-specific proteins that are otherwise inaccessible to standard monoclonal antibodies. Current therapeutic modalities include bispecific T-cell engagers (e.g., Tebentafusp) and TCR-engineered T-cell therapies (e.g., Afamitresgene autoleucel), which utilize T-cell receptor-based binding domains to achieve high specificity for the pMHC complex. By engaging these targets, drugs can redirect the patient's T-cells to recognize and lyse melanoma cells with high precision. However, successful targeting requires both the presence of the specific HLA allele and sufficient expression of the target antigen within the tumor (Immunocore, 2024; Adaptimmune, 2024). This class of targets represents a significant advancement in precision oncology, particularly for tumors with low mutational burdens or those lacking traditional surface targets.

Other names

HLA-peptide complexMHC-restricted tumor antigenTumor-specific pMHCMelanoma-associated pMHCpMHC complex

The primary mechanisms of action for drugs targeting melanoma-associated pMHC complexes include T-cell redirection and adoptive cell transfer. Bispecific T-cell engagers, such as ImmTACs, utilize a high-affinity TCR domain to bind the pMHC on tumor cells and an anti-CD3 domain to recruit and activate polyclonal T-cells (Nathan et al., 2021, NEJM). TCR-engineered T-cell therapies (TCR-T) involve the infusion of autologous T-cells modified to express a specific TCR that recognizes the target pMHC, leading to direct, MHC-restricted cytotoxic activity against the tumor (D'Angelo et al., 2024, Lancet).